This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Mumbai: Indian shipping firms are threatening to “flag out” and register in foreign territories if the government removes one of the last few protections that they still enjoy. Great Eastern Shipping and Shreyas Shipping —two of the largest private shipping lines in the country—are mulling the option of moving to more tax-friendly jurisdictions as the government gradually removes these benefits.
Great Eastern Shipping Ltd today said its board will next month decide on raising up to Rs 1,000 crore through private placement of non-convertible debentures (NCDs).
Great Eastern Shipping Company has taken delivery of a second-hand very large gas carrier ‘Jag Viraat’ (2007 built) of about 81,617 cbm. The company had contracted to buy the vessel earlier this month. GE Shipping’s current fleet stands at 48 vessels, comprising 33 tankers (12 crude carriers, 17 product tankers, 4 LPG carriers) and 15 dry bulk carriers (1 capesize, 8 Kamsarmax, 6 Supramax) with an average age of 10.
3:30 pm Market Closing: Benchmark indices continued to trade higher for second consecutive session, with the Sensex rising 107.98 points to 33,174.39, tracking positive move in global equities.
500325 533096 TCHQY ICLQY 511218 TALBROAUTO BJJQY EICHERMOT RLNIY GLENMARK JETAIRWAYS 532702 511196 532822 532942 CNRYY KNRCON 500182 AXBA BAJAJFINSV FORTIS 500180 500620 CANBK SSWL 500188 HINDZINC 532938 IDBI RIFS PUNJLLOYD 539336 SRTRANSFIN 500390 532388 505200 IDFCBANK AXISBANK 505160 JMCPROJECT RIGD HEROMOTOCO BHARTIARTL 500034 TATAMETALI AXBKY RELINFRA ICICIBANK HDB HRTQY IOB GESHIP CAPF GSPL VINATIORGA 532755 S68 539437 532483 SRRQY 522287 GAILF SBAZ GICHSGFIN 517496 SYNGENE RICOHQ SPXCF RELEY AXB RELFF 539268 CANFINHOME 511676 TECHM SPXCY GUJGAS BAJFINANCE TATASTEEL TATLY GAILY RIFA 513262 RELIANCE 532617 HNDZY 532978 BHRQY GLKQY 532215 500470 524200 522263 HDFCBANK UBNC ECQRY 500116 IBN 513434 532843 532179 532454 TTST 532693 532296 CRPKY 532174 IDEA KALPATPOWR CORPBANK ADANIPOWER
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...